Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Pasireotide
open-in-new
<h2 id="references">References</h2> <ol> <li id="fn:1"><p>"Drug Approval Package: Signifor (pasireotide) Injection NDA #200677". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 13 May 2020. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000TOC.cfm" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000TOC.cfm</a> <a href="#fnref:1" class="footnote-back-ref">↩</a></p></li> <li id="fn:2"><p>"Signifor EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/signifor" target="_blank">https://www.ema.europa.eu/en/medicines/human/EPAR/signifor</a> <a href="#fnref:2" class="footnote-back-ref">↩</a></p></li> <li id="fn:3"><p>"Summary of Product Characteristics: Signifor" (PDF). European Medicines Agency. Archived from the original (PDF) on 14 June 2018. Retrieved 27 September 2016. <a href="https://web.archive.org/web/20180614200149/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf" target="_blank">https://web.archive.org/web/20180614200149/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf</a> <a href="#fnref:3" class="footnote-back-ref">↩</a></p></li> <li id="fn:4"><p>"Pasireotide Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 13 May 2020. <a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=288709" target="_blank">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=288709</a> <a href="#fnref:4" class="footnote-back-ref">↩</a></p></li> <li id="fn:5"><p>"EU/3/09/671". European Medicines Agency. 17 September 2018. Retrieved 13 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. <a href="https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu309671" target="_blank">https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu309671</a> <a href="#fnref:5" class="footnote-back-ref">↩</a></p></li> <li id="fn:6"><p>Mancini T, Porcelli T, Giustina A (October 2010). "Treatment of Cushing disease: overview and recent findings". Therapeutics and Clinical Risk Management. 6: 505–16. doi:10.2147/TCRM.S12952. PMC 2963160. PMID 21063461. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963160" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963160</a> <a href="#fnref:6" class="footnote-back-ref">↩</a></p></li> <li id="fn:7"><p>"Signifor EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/signifor" target="_blank">https://www.ema.europa.eu/en/medicines/human/EPAR/signifor</a> <a href="#fnref:7" class="footnote-back-ref">↩</a></p></li> <li id="fn:8"><p>"Signifor- pasireotide injection". DailyMed. 15 January 2020. Retrieved 13 May 2020. <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2" target="_blank">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2</a> <a href="#fnref:8" class="footnote-back-ref">↩</a></p></li> <li id="fn:9"><p>"Signifor LAR- pasireotide kit". DailyMed. 17 December 2019. Retrieved 13 May 2020. <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5504116c-d531-4d47-b160-41c6671d52aa" target="_blank">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5504116c-d531-4d47-b160-41c6671d52aa</a> <a href="#fnref:9" class="footnote-back-ref">↩</a></p></li> <li id="fn:10"><p>"Signifor EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/signifor" target="_blank">https://www.ema.europa.eu/en/medicines/human/EPAR/signifor</a> <a href="#fnref:10" class="footnote-back-ref">↩</a></p></li> <li id="fn:11"><p>"EMEA Approval for Pasireotide". Archived from the original on 4 February 2014. Retrieved 26 January 2014. <a href="https://web.archive.org/web/20140204042347/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Fhuman%2Forphans%2F2009%2F11%2Fhuman_orphan_000677.jsp" target="_blank">https://web.archive.org/web/20140204042347/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Fhuman%2Forphans%2F2009%2F11%2Fhuman_orphan_000677.jsp</a> <a href="#fnref:11" class="footnote-back-ref">↩</a></p></li> <li id="fn:12"><p>"Drug Approval Package: Signifor (pasireotide) Injection NDA #200677". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 13 May 2020. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000TOC.cfm" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000TOC.cfm</a> <a href="#fnref:12" class="footnote-back-ref">↩</a></p></li> <li id="fn:13"><p>"FDA Approves Pasireotide for Cushing's Disease". <a href="http://www.medscape.com/viewarticle/776273" target="_blank">http://www.medscape.com/viewarticle/776273</a> <a href="#fnref:13" class="footnote-back-ref">↩</a></p></li> <li id="fn:14"><p>"Signifor LAR (pasireotide) for injectable suspension". U.S. Food and Drug Administration (FDA). 1 March 2016. Retrieved 13 May 2020. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203255Orig1s000TOC.cfm" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203255Orig1s000TOC.cfm</a> <a href="#fnref:14" class="footnote-back-ref">↩</a></p></li> <li id="fn:15"><p>"Signifor EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/signifor" target="_blank">https://www.ema.europa.eu/en/medicines/human/EPAR/signifor</a> <a href="#fnref:15" class="footnote-back-ref">↩</a></p></li> <li id="fn:16"><p>Tucker ME (17 December 2014). "FDA Approves Pasireotide for Treating Acromegaly". Medscape. Retrieved 2 August 2015. <a href="http://www.medscape.com/viewarticle/836728" target="_blank">http://www.medscape.com/viewarticle/836728</a> <a href="#fnref:16" class="footnote-back-ref">↩</a></p></li> </ol>